Search for: "MERCK & CO., INC. " Results 101 - 120 of 669
Sort by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
30 Dec 2016, 2:58 pm
Permission to appeal in patent cases - farewell to the Pozzoli approachGuest Kat Eibhlin Vardy recaps the case Teva UK Ltd v Boehringer Ingelheim Pharma GmbH & Co KG, [2016] EWCA Civ 1296. [read post]
14 Nov 2016, 9:16 am by Dennis Crouch
The Merck petition is focused on pre-AIA patents. [read post]
13 Jun 2016, 7:09 am by Editors
In a decision that will certainly be appealed, a judge ruled that in-house lawyer misconduct will result in a company losing out on quite a hefty sum: “A U.S. judge on Monday found a pattern of misconduct by Merck & Co including lying under oath and other unethical practices, freeing Gilead Sciences Inc from paying any damages for infringing Merck’s patents with its lucrative treatments for hepatitis C…The dramatic ruling comes… [read post]
17 May 2016, 11:25 am by Tom Lamb
About 4,400 Cases Still Pending In Federal Court MDL As Well As New Jersey And California State Courts   (Posted by Tom Lamb at DrugInjuryWatch.com)   In their corporate report Form 10-Q for the first quarter of 2016, Merck & Co., Inc. provided investors and others with their most recent update about what has been going on (or has not been, as it might seem to be the situation) with the thousands of Fosamax - femur fracture cases filed against the drug… [read post]
31 Mar 2016, 7:07 am by Docket Navigator
Merck & Co., Inc. et al, 1-15-cv-00572 (DED March 29, 2016, Order) (Sleet, J.) [read post]
28 Mar 2016, 2:59 am
It addresses declaratory reliefs, jurisdiction to grant them, and delves into the leading case on declaratory relief in patent cases -  ie Arrow Generics Ltd v Merck & Co Inc [2007] EWHC 1900. [read post]
25 Mar 2016, 2:11 pm
 Such a declaration takes support from Arrow Generics Ltd v Merck & Co Inc .FKB's declaration intends to establish that its products were anticipated or obvious at the priority dates of the two patents. [read post]
19 Mar 2016, 11:10 am by Gregory B. Williams
Merck & Co., Inc., et al., Civil Action No. 15-560-GMS (D.Del., March 17, 2016), the Court denied defendant’s motion to dismiss the complaint which argued that the patent-in-suit, United States Patent No. 9,067,999 (“the ‘999 patent”), claims ineligible subject matter pursuant to 35 U.S.C. [read post]
19 Mar 2016, 11:10 am by Gregory B. Williams
Merck & Co., Inc., et al., Civil Action No. 15-560-GMS (D.Del., March 17, 2016), the Court denied defendant’s motion to dismiss the complaint which argued that the patent-in-suit, United States Patent No. 9,067,999 (“the ‘999 patent”), claims ineligible subject matter pursuant to 35 U.S.C. [read post]
29 Feb 2016, 4:43 pm by Kevin LaCroix
Taylor, 782 F.3d 1142 (10th Cir. 2015); In re Merck & Co., Inc. [read post]